ImCheck Therapeutics

ImCheck Therapeutics

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic with a focus on γ9δ2 T cells

ImCheck Therapeutics is designing and developing novel immunotherapeutics that target members of the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules with an initial focus on gamma delta (γ9δ2) T cells. ImCheck’s understanding of these novel targets benefits from the continued involvement of company scientific founder Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille University), a world-renowned researcher in γ9δ2T cells and BTNs, which has led to identification of additional immune cell populations that can be modulated through BTN(L)s, including tumor associated macrophages (TAMs).

ImCheck’s expertise in antibody-based drug discovery and translational research have enabled us to advance our first immuno-oncology program targeting BTN3A to activate γ9δ2T cells into the clinic in 2020 and to produce a broad pipeline of monoclonal antibody drug candidates.

Due to their mechanism of action, including the ability to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class" antibodies may be able to improve upon the first-generation of checkpoint inhibitors in cancer. ImCheck’s programs also have potential in autoimmune and infectious disease indications, which the company is currently investigating.

Leadership Team

Pierre d'EPENOUX
Pierre d'EPENOUXChief Executive Officer

Paul FROHNA
Paul FROHNAMD, PhD, PharmD
Chief Medical Officer
Loui MADAKAMUTIL
Loui MADAKAMUTILPhD
Chief Scientific Officer
Hans Henrik CHRISTENSEN
Hans Henrik CHRISTENSENChief Financial Officer and
Chief Operating Officer
Claude KNOPF
Claude KNOPFChief Business Officer

Board Members

Debasish ROYCHOWDHURY
Debasish ROYCHOWDHURYMD
Independent Chairman
Michael BARAN
Michael BARANPhD, MBA
Pfizer Ventures
Vincent BRICHARD
Vincent BRICHARDMD, PhD
Life Sciences Partners
Rémi DROLLER
Rémi DROLLERPhD
Kurma Partners France
Pierre d'EPENOUX
Pierre d'EPENOUXChief Executive Officer

Karl NÄGLER
Karl NÄGLERPhD
Wellington Partners Life Sciences
Thibaut ROULON
Thibaut ROULONPhD
Bpifrance
Bram VANPARYS
Bram VANPARYSPhD, MBA
Gimv

Board Observers

Klaus BREINER
Klaus BREINERPhD
BB Pureos Bioventures
Philipp MÜLLER
Philipp MÜLLERPhD
Boehringer Ingelheim Venture Fund
Geeta VEMURI
Geeta VEMURIPhD, MBA
Agent Capital

Clinical Advisory Board

Daniel OLIVE, MD, PhD, Chairman
Daniel OLIVE, MD, PhD, ChairmanHead of the Immunity and Cancer lab, CRCM.
Professor of Immunology and
Director of the Oncology Research Programs
at Aix Marseille University.
Scientific Founder of ImCheck.
Marc BONNEVILLE, DVM, PhD
Marc BONNEVILLE, DVM, PhDVice President of Medical and
Scientific Affairs at Institut Mérieux.
Scientific and Medical director,
deputy General Manager
Fondation Mérieux.
Richard BULLER, MD, PhD
Richard BULLER, MD, PhDOncology Diagnostic and
Clinical Development
Consulting, LLC.
Johann de BONO, MD, PhD
Johann de BONO, MD, PhDRegius Professor of
Cancer Research.
Professor of Experimental
Cancer Medicine and Honorary
Consultant in Medical Oncology.
Jean Jacques FOURNIE, PhD
Jean Jacques FOURNIE, PhDResearch Director at CNRS
(French National Center for
Scientific Research) in Cancer
Research Center of Toulouse.
Richard D. LOPEZ, MD
Richard D. LOPEZ, MDAssociate Professor of Medicine
Cell Therapy and Hematologic
Malignancies Specialist.
General Oncology.
Aurélien MARABELLE, MD, PhD
Aurélien MARABELLE, MD, PhDClinical Director,
Cancer Immunotherapy Program,
Gustave Roussy, Paris.
Director, Translational Research
Laboratory in Immunotherapy,
INSERM.
Jeffrey WEBER MD, PhD
Jeffrey WEBER MD, PhDDeputy Director of the
Laura & Isaac Perlmutter
Cancer Center and
Head of Experimental Therapeutics.
Professor of Medicine at the
NYU Langone Medical Center.

Investors

 
Kurma Partners
IDinvest Partners
LSP
GIMV
Bpifrance
 
Pfizer
Wellington Partners
Boehringer Ingelheim
Agent Capital
 Alexandria Venture Investments
 
Pureos

ImCheck’s translational research platform, where the company conducts its discovery and development research for a new generation therapeutic antibodies, has been financially supported by the European Union through its European Regional Development Fund.

The amount granted was: €717,000

The next game-changer in immuno-oncology

Pierre d'EPENOUX

Chief Executive Officer

The next game-changer in immuno-oncology

ImCheck’s first clinical trial with ICT01 is based on comprehensive translational research supporting its potential to activate γδ T cells to kill malignant cells. The Series B funding, bringing the total capital raised to $91 million in a little over three years, allows us to accelerate the development of our unique immuno-oncology pipeline, further investigate the potential of our antibodies in autoimmune disease, and establish clinical operations and corporate development activities in the US.